Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron vs Cold Exposure for BAT Activation
NCT02811289Completed
- Sponsor
- Université de Sherbrooke
- Start
- Aug 2016
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of mirabegron in type 2 diabetes mellitus (T2DM) and obesity (2 arms), sponsored by Université de Sherbrooke. Primary endpoints: Brown Adipose Tissue net glucose uptake at 2 years, Brown Adipose Tissue oxidative metabolism at 2 years and 2 more. Started Aug 2016; status: completed.
02
Drugs
mirabegron
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02811289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02811289.